What Happened?
New York, NY-based Oramed Appointed Nadav Kidron as Chief Executive Officer
About the Company
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
About the Person
Nadav Kidron is Chief Executive Officer at Oramed. Previously, Nadav held various senior HR leadership roles in the industry.
Info Source
News
Short Profile